Lumida
/KIDS
⌘K
OrthoPediatrics Corp

OrthoPediatrics Corp

KIDS
$19.22USD↓-5.72%-1.16 today

MARKET CAP

493.5M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$19 – $20

52W RANGE

$14
$24

AI Summary

Stalk
Sell NowHigh

KIDS remains in a Stage 4 decline with confirmed lower highs and lows and price below all key moving averages; there are no signs of selling exhaustion, volume and volatility support further downside, and both medium- and short-term signals align with a bearish continuation, favoring selling on breakdown into the next support area.

  • ↑Q1 2026 revenue $59.4M (+13% YoY); full-year guidance $263–267M.
  • ↑International revenue rose 22% YoY; expects it to outgrow domestic.
  • ↓Negative earnings yield highlights difficulties in generating returns.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

OrthoPediatrics Corporation (NASDAQ: KIDS) is a prominent player in the pediatric orthopedic market, developing surgical solutions specifically designed for children. The company focuses on trauma, deformity correction, scoliosis, and specialty bracing, addressing the unique needs of a largely underserved patient population. OrthoPediatrics is well-positioned in a growing sector with a commitment to innovation and a robust product pipeline tailored for pediatric care. Recent strategic moves, including international expansion and innovative product launches, position OrthoPediatrics favorably within broader trends in pediatric healthcare.

Bull says

  • ↑Q1 2026 revenue $59.4M (+13% YoY); full-year guidance $263–267M.
  • ↑International revenue rose 22% YoY; expects it to outgrow domestic.
  • ↑Gross margin sustained at 73% with positive operating leverage.
  • ↑Capex cut to $2.3M; targeting free cash flow breakeven in 2026.
  • ↑Launching VertiGlide and 3P HIP under multi-year innovation cycle.
  • ↑Strong quantitative scores and effective debt management support stability.

Bear says

  • ↓Negative earnings yield highlights difficulties in generating returns.
  • ↓Operating expenses surged 18% YoY to $54.7M, pressuring margins.
  • ↓Product launches face execution risks around approvals and timing.
  • ↓Heavy international exposure risks volatility in LATAM and EMEA markets.
  • ↓Mixed analyst revisions and moderate buy ratings imply limited upside.
  • ↓Weak profitability factors and elevated short interest underscore skepticism.

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 05-30-2026bullish

Transcript signals

Bull points

  • We're replacing that spica cast with a hip brace. And so there's really no market data that tells us the size of that. But what I can tell you is that this phrase is quickly becoming the new standard of care and is absolutely winning over surgeons left and right.
  • In the first quarter alone, we supported the treatment of nearly 39,000 children, bringing our total impact to over 1.175 million kids helped since our inception.
  • Our global revenue growth of 17% is a result of executing in each of these areas. Our efforts to scale OPSB are advancing steadily. Execution of the OPSB strategy and further clinic expansion is on track and driving total OPSB growth of better than 20%."

Bear points

  • Total operating expenses increased $7.3 million or 18% compared to the prior year period to $49.2 million in the first quarter of 2025. The increase was primarily driven by incremental personnel required to support the ongoing growth of the company, including increased non-cash stock compensation, as well as the addition of OPSB clinics.
  • Research and development expenses decreased $0.6 million in the first quarter of 2025 due to the timing of product development third-party invoice during the first quarter of 2025.
  • Adjusted EBITDA was a loss of $0.4 million in the first quarter of 2025, over 50% improvement when compared to a loss of $1.1 million for the first quarter of 2024.
Read full transcript analysis ›